Territory Manager - Naperville, IL
Mineralys Therapeutics
Job Description
<p>“<a href="https://himalayas.app/companies/mineralys-therapeutics">Mineralys Therapeutics</a> is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=wdnYvBs2TrTUXO7lTCbpViEDUmu9yMCV38XKZg3HIdwtJmMY6rvT70Nxd3r3-oU3H0VOnMZvoUmvoqC6nG_Pjg01Ih96gnY07mU8QWVEZn1GR2bOdJxMZE-0Yalo_8hBG4CswY6tftJNG9LB_p9kPMEbk6GoOdwfprNlseLwtQlqCZfwmuhwM5sx3w9xiWoumwnob5VqMpfYj83bBcSw5piaLVqHQfCx1iSzAYzJfojgXfl59dQRpeNEz34fRw_70CWqdKdHyo-XTu1HLN7cH5FrNTZIBG_Hlmnn6yoOfw_nlwaaVUX3kQZ5AarYCb9h7LI1_zbAzVYg6saQIhf_eN4eXxM8r_f6vseBm6UzwFGlfCl-PRmt_PkWzySCzw3L2Hw4riuF_qBjd519Mwau-aEC_P3641l5GQlvKe45ctDpy-9xkJRSxd1cEx4R1pgm7JZNbVexqKMMDMg65bWUS6-kF8zrt1fSbaOcEX8qf3taEmavhZt4WQs2jnSFfDaPily2twy8X-mbU8vde_Y145vWG0_atPW_bsVtf-shSYRPwJdsBMSxR33oVbqEQORBVHs78sPiGazAgU_4hLcRSXbBQolSwhXO9ysjo2ITclbDK_YfuelVo3qta5o7NB5nrIuQ1IU0epy7_Ybj8Jtl5PKP2xSGgL3Oe6dl7t67PWXX-i4W0U_4fb2ud5DTq-IM9DUGD4o9Mzq_iqSob3yHnRYGFBQIQE18GyrppPkIaZsNhXtuLHF4ZE1Lia1_N3V3m8d8kYgQbbeP4wcgRkD4UvdH0NrW-rDnQKIl2DsWyEQ=" rel="nofollow ugc noopener noreferrer" target="_blank">https://mineralystx.com</a>. Follow Mineralys on <a href="https://www.globenewswire.com/Tracker?data=zw6m2uZ0IkO8jI_Dg-ijWdTmwg3Ntv7s3tI9ITw4-N3fE3kKec_DOPWsFtEMZ376vC7ruxz8f-9lj30I_0_iUJ3tZKk8GM0ERtmyUOpvfAdMtg_ZBt5rSlvpFjKfhOtrJm9cSoTrcGHjhjj-prr8t5UH3OfiOtCwU8M7HKspLppWfyf4Hpj3D_enArI160Q-gkaoCJGjUZA24_dfp_cQeiu6z3xgZOnG3F8msqZn554VnyK4ulrUp0RcQXzoTLzuoxr0RTFDe4Wsc06mhV-KZi7BalE9SDwAGgHwzLpvanFifR-4Pb-p9sQCmix10HggznU8WUuAX2Z_dojpumO3fVinLxY0PyNxyy3HA-CV-e8XjbMbk2_t0quL_VPqOrLCazhU2Ny2qnArdlkVVtgV1n3rluj8NeCg0Spp7JAQ9mcv6U09rYt-MqBn7Ta-9K7CKDof7M1tQOItlwALoNOsU6eHUwy5sTWFosczNcbOq41RLhXbvkounRGgfA-u5jszuZbHmNFWTQ8lqVsTLhSxL7ObH7udW0CrOiaSwUvwq26xORXZPFjZJsvLC8XxfuRR7WLveEeqQFI5UrXzi6xiOsDddciQbwoy8Sab3wtwPgwSO09Tc1svbVaS6YwuGrNCUPGAiCqK3bj9KrkfTpD5X1T5IIfJMrTUqUTf4gtjFoUutc8Gcvkwvzau508rALSHkyk6A82HNfX8DkCXaQeGM_lpa7PxB9TxUcPelVC38JBqaB8xtZUujfP_oVWEXXgJo-CeitFUipIn4VBVVTIVFO3bgln4EwCEJa1LenGOeraktD-pyc1wakxNbPj3e3LkGDUxT3RaHDDqkEIDfXgC9Ij6PClRzCjtKS-xs8wXtAs=" rel="nofollow ugc noopener noreferrer" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=ctmNVA0-ODmDAOFMt8zvnBxTA0ediZU8vD2Rp82xMBkO1mbPZL2FmOvaawpQQvNOY4ajj9DRmNVjW_3PkU2TF_VLntN--78omfkLqWRmQszC15E6tqAqXWairTw9h8KgGIqs_CH66Lf5BQlcKYdwMDOfzHTC3g_Maw6rXLVPqywTM9HAwi6_o6VCibNYr5iOPBY-3iyJjBKS4b6_z_9JDB4k1Y3K7FXL-7_yvhl0j1yyj0q9CjoWyCm0Wm8-tll8xv7dLyc51p6204GieUrKCBuEUHGMbLMCJo5PLThPx8CZd-EHmRdMO9Fpi0AZrih6fcgcBGDuxnpgi4vjZYatJetL10zFpt4bqmWNKsKxAzlNUx06dBXWLjvOo-C-BiKb4iB491RKluONuRoV_-XUi11h2CK